Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MMEX Met>with>Investment>Banks>NYC***Engagement>Letter> pending***>FINANCING>COMPLETE
Apr. 18, 2017: Meetings with Investment Banks NYC, Engagement Letter pending
Co. Mile Stones Just Posted on MMEX Website!
http://www.mmexresources.com/project_milestones.php
Recent project milestones for the Pecos County refinery project are listed below:
Apr 27, 2017: Technical Conference Status Meeting with Consultants, EPC/Environmental/Strategic Planning
Apr 25-26, 2017: Pecos County Land site survey completed
Apr. 18, 2017: Meetings with Investment Banks NYC, Engagement Letter pending
Apr. 13, 2017: Environmental Firm retained to prepare and process necessary State/Federal Permits
Apr. 12-13, 2017: Crude oil supply follow-up meetings; Draft of LOI submitted
Mar. 25, 2017: Engineering, Procurement and Construction (EPC) Company retained
Feb. 27, 2017: Strategic Consultant and Industry Advisor retained
Feb. 20, 2017: Pecos County Land Purchase and Sale Agreement Executed (500 acres)
Feb. 15, 2017: Public Relations Firm retained
Feb. 14, 2017: Pre-permit meeting held with Texas Commission on Environmental Quality (TCEQ)
View Project Overview
View Progress Photos / Video
Meetings>with>Investment>Banks>NYC******Engagement Letter pending******>MMEXcellent FINANCING COMPLETE?!
Co. Mile Stones Just Posted on MMEX Website!
http://www.mmexresources.com/project_milestones.php
Recent project milestones for the Pecos County refinery project are listed below:
Apr 27, 2017: Technical Conference Status Meeting with Consultants, EPC/Environmental/Strategic Planning
Apr 25-26, 2017: Pecos County Land site survey completed
Apr. 18, 2017: Meetings with Investment Banks NYC, Engagement Letter pending
Apr. 13, 2017: Environmental Firm retained to prepare and process necessary State/Federal Permits
Apr. 12-13, 2017: Crude oil supply follow-up meetings; Draft of LOI submitted
Mar. 25, 2017: Engineering, Procurement and Construction (EPC) Company retained
Feb. 27, 2017: Strategic Consultant and Industry Advisor retained
Feb. 20, 2017: Pecos County Land Purchase and Sale Agreement Executed (500 acres)
Feb. 15, 2017: Public Relations Firm retained
Feb. 14, 2017: Pre-permit meeting held with Texas Commission on Environmental Quality (TCEQ)
View Project Overview
View Progress Photos / Video
OUTSTANDING! HUGE! Please Sticky!>Apr>18>2017:>Meetings>with> Investment>Banks>NYC,******Engagement Letter pending******
All Just Posted Below on MMEX Website!
http://www.mmexresources.com/project_milestones.php
Recent project milestones for the Pecos County refinery project are listed below:
Apr 27, 2017: Technical Conference Status Meeting with Consultants, EPC/Environmental/Strategic Planning
Apr 25-26, 2017: Pecos County Land site survey completed
Apr. 18, 2017: Meetings with Investment Banks NYC, Engagement Letter pending
Apr. 13, 2017: Environmental Firm retained to prepare and process necessary State/Federal Permits
Apr. 12-13, 2017: Crude oil supply follow-up meetings; Draft of LOI submitted
Mar. 25, 2017: Engineering, Procurement and Construction (EPC) Company retained
Feb. 27, 2017: Strategic Consultant and Industry Advisor retained
Feb. 20, 2017: Pecos County Land Purchase and Sale Agreement Executed (500 acres)
Feb. 15, 2017: Public Relations Firm retained
Feb. 14, 2017: Pre-permit meeting held with Texas Commission on Environmental Quality (TCEQ)
View Project Overview
View Progress Photos / Video
WARNING: Don't Get Caught>Flipping>MMEX>FINANCING>News>ANYTIME>Now
MMEX VIA Hanks>Financing>BASED>ON>VALUATION>RPT>Financing>News>Due>Anytime>
OCMillionaire Member Level Wednesday, 04/19/17 10:19:13 AM
Re: OCMillionaire post# 44352
Post # of 45659
Financing update 2nd part and Valuation:
******I found the company who gave them part of the financing. I stumbled on it last night so I called MMEX to confirm and he said,
****** I am going to have to wait for the news to see if I am right Oh my gosh this is huge. Going to buy 2-5 million more today :)
The valuation as well I found out, is worth close to what STERVC has posted via company word of mouth. I asked about the .58 cent valuation and his response was:
Sounds like you have done some extensive research. Looks like Doty Scott isn't the only one who can do math.
I don't know about you guys but uhm......what does that exactly mean other than its worth around there?!!!!!
Guys, no one gives them THIS MUCH money if its a scam....and oh boy they got a lot for the first round!!!
Also, I will be respectful of the companies wishes and let them tell the story.
MMEX VIA Hanks>Financing>BASED>ON>VALUATION>RPT>Financing>News>Due>Anytime>
OCMillionaire Member Level Wednesday, 04/19/17 10:19:13 AM
Re: OCMillionaire post# 44352
Post # of 45659
Financing update 2nd part and Valuation:
******I found the company who gave them part of the financing. I stumbled on it last night so I called MMEX to confirm and he said,
****** I am going to have to wait for the news to see if I am right Oh my gosh this is huge. Going to buy 2-5 million more today :)
The valuation as well I found out, is worth close to what STERVC has posted via company word of mouth. I asked about the .58 cent valuation and his response was:
Sounds like you have done some extensive research. Looks like Doty Scott isn't the only one who can do math.
I don't know about you guys but uhm......what does that exactly mean other than its worth around there?!!!!!
Guys, no one gives them THIS MUCH money if its a scam....and oh boy they got a lot for the first round!!!
Also, I will be respectful of the companies wishes and let them tell the story.
NAFS 101-43 PR Coming This Week.>Spoke to>CEO>4/27>was>Very>Up-beat>told>me>Fillings>done>(10k posted a few minutes after we spoke lol) Survey done ( said he's Very happy with 43-101 results after I asked him if he was happy with them! ) He also Said watch for PR's next few days!
Last Chance No For Cheap Shares Right Now.
MMEX Stair Stepping>Up>On>Low>Vol>Float>Lockup>KABOOM>SOON
Disagree, MMEX on>verge>of>National>Media>Coverage>&>More>Local>Exposure>Besides>all>The>Latest>News>Developments>in>Process
***BEFORE YOU READ ANYTING ELSE ABOUT THIS AMAZING COMPANY PLEASE READ PROPHETABLES STICKY BELOW***
$15 million dollar cash infusion by secret health care investor. Investors kept buying at .26 average, spending half there salary buying shares on the open market. Multi Dollars double digit dollars and triple digit dollars in the horizon. Anything under .10 is a gift.
1. Pre-Clinical Studies To Be Completed 2nd Q 2017
2. Application for IND Orphan Drug Status for its Cytotronics Product
3. Over 20 Patent Applications OWNED by the CEO and the Company
4. 10 Form 4s filed since Dec 2016 for Insider purchases of stock
5. A "Strategic Healthcare" Institutional Investor has Ponied up $15 mil to buy back Converts
6. Company paying off the rest of its debt with $2.2 million
7. Uplistment to a "National" exchange being considered
8. Has won their injunction against Kodiak Capital and other Financiers for diluting the stock
Endonovo Evaluating Therapeutic Potential of Non-Invasive Electroceutical Device Following Myocardial Infarction
Electromagnetic pulses are responsible for many of the activities in our bodies. They are an integral part of what keeps our hearts beating and brains functioning.
The bioelectronics device is a portable Time-Varying Electromagnetic Field (TVEMF) system. The unit uses a sophisticated miniaturized circuit board that delivers the specifically designed and patented electromagnetic field to a designated area of the body through the use of antennas (coils).
TVEMF>(ENDV Patented Tech) vs PEMF>(ALL Others)
Time-Varying Electromagnetic Field (TVEMF) technology is fundamentally different from other magnetic pulse devices. TVEMF is based on the physics of electricity and magnetism as well as the physiology of cells and tissues.
PEMF devices do not produce square waves, the optimal waveform for a tissue response.
PEMF devices do not produce enough intensity to stimulate a response; most do not even produce 1 Gauss of intensity.
PEMF devices do not produce a rate of induction (slew rate) that is quick enough to penetrate deep within tissues. TVEMF produces pulses that are only 0.0001 seconds wide.
Furthermore, TVEMF features repeating patterns of pulses that are selected based on known motor-neuron stimulation patterns of musculoskeletal tissues.
Why Square Waves?
Sine waves take too long to reach their peak intensity. The lower slew rate means that they are not effective in producing a cellular/tissue response.
Triangle and sawtooth waves also suffer from a lower slew rate, meaning that they are not effective in producing a cellular/tissue response.
Endonovo’s TVEMF device produces a patented square waveform, which was proven the most effective waveform to increase cell growth and the production of over 200 growth factors and cytokines.
Cytotronics™ Platform
Our Cytotronics™ platform uses Time-Varying Electromagnetic Field (TVEMF) technology to expand and enhance the therapeutic properties of stem cells, immune cells and for use in tissue engineering. The goal of our Cytotronics™ platform is to create optimized cell-based therapies with greater therapeutic potential than the un-modulated cells currently being used in regenerative medicine.
The origins of our Cytotronics™ platform dates back to experiments conducted at NASA to expand stem cells ex vivo and to create therapies that could be used to treat astronauts during long term space exploration. The results of those experiments revealed that Time-Varying Electromagnetic Fields (TVEMF) could be used to expand stem cells in the lab and resulted in the increased expression of dozens of genes related to cell growth, tumor suppression, cell adhesion and extracellular matrix production.
A Physics Approach to Biology – Ex Vivo Modulation
We have built upon over 15 years of research and development to create a novel therapeutic paradigm – the systematic enhancement of the biological and therapeutic properties of cells ex vivo. This allows for the creation of a precise, scalable and cost effective approach to maximize the safety and effectiveness of cell-based therapies.
While our competitors are using genetic modification and pharmacological modulation to alter and enhance the biological properties of cells, we are taking A Physics Approach to Biology™ in the use of bioelectronics to create ex vivo modulated cells with enhanced biological and therapeutic properties. Using our Cytotronics™ platform, we are able to create cells that express higher levels of key genes related to stem cell maintenance, cell growth, cell homing and engraftment. Cytotronic™ expansion of peripheral blood stem cells resulted in an over 80-fold expansion of CD34+ cells in as few as 6 days.
Our Cytotronic™ platform was shown to be able to maintain normal human neural progenitor (NHNP) cells in long term culture (180 days), undifferentiated with the ability to be cryogenically preserved then subsequently reintroduced into culture with stem and progenitor markers still intact. NHNP cells that were expanded using our technology were then shown to not be tumorigenic when introduced into nude (athymic) mice for 85 days. Multi-color Fluorescence In Situ Hybridization (mFISH) showed that there was no chromosomal damage to cells subjected to Time-Varying Electromagnetic Fields (TVEMF).
Perivascular Cell Therapy Created Using Cytotronics™
Each year, an estimated 60,000 patients with leukemia and lymphoma need bone marrow transplantation. However, only 25,000 of those patients actually receive a transplant, primarily because the other 35,000 patients are unable to find a fully matched bone marrow donor.
Umbilical cord blood from newborn children is an excellent source of hematopoietic stem cells for stem cell transplants because their immune system is still immature and the stem cells have a lower probability of inducing an adverse immune response in patients. Furthermore, a perfect immunological match between donor and recipient is not necessary, unlike in bone marrow transplants.
However, in most cases a unit of umbilical cord blood contains too few stem cells to treat an adult patient and its use is confined above all to the treatment of children. Numerous patients have better matched cord blood products available (5/6 or 6/6 HLA match), however those products have low cell doses and are not suitable for use in adult patients. This is one of the reasons why less than 3 percent of cord blood collected in the United States is ever used. Low volume cord blood units present the opportunity to expand and/or enhance these unused cord blood units for the widespread use of hematopoietic stem cells in regenerative medicine.
Off-The-Shelf Therapeutic
Our Perivascular Cell Therapy is created using immunologically privileged and immune-modulating stem cells from a portion of the human umbilical cord and co-cultured with adipose-derived stem cells along with cord blood cells to create a perivascular cell mixture that can be used to treat malignant and non-malignant hematological disorders.
Endonovo’s cell therapy is an off-the-shelf therapeutic that can be stored indefinitely in a low temperature freeze without requiring cryopreservation. Our technologies are particularly suited to expand the use and effectiveness of low-volume cord blood units.
More In Vivo-Like Stem Cells
Our off-the-shelf therapeutic is created in a three-dimensional bioreactor using our proprietary Cytotronics™ platform to further expand and enhance the biological properties of the stem cells within the perivascular cell mixture. Our use of a perivascular co-culture in a three-dimensional bioreactor is meant to mimic the way that blood-forming stem cells renew and reside in the body. This simulated stem cell niche allows for the expansion of long-term self-renewing stem cells. Researchers had previously identified endothelial and perivascular cells as the cells that were functionally responsible for the maintenance of blood-forming stem cells (HSCs) in the body. Our technologies provide a method for the expansion of HSCs in an environment that resembles their native stem cell niche..
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=129419388
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=129638466
$15 million dollar cash infusion by secret health care investor. Investors keep buying at .26 average this spending half there salary buying shares on the open market. Multi Dollars double digit dollars and triple digit dollars in the horizon. Anything under .10 is a gift. Soon it will be anything under .26 is a gift.
$ENDV
MLGT China RM: 24mill FLT-New Address&phone>#>of>Chinese>owners>Shenzhen>
NOTE: The address is in one of the hottest tech industrial complexes in the world, the Shenzhen Software Industry Base.
Link:
http://ih.advfn.com/p.php?pid=nmona&article=74399925
If someone happens to be in the area, perhaps you can stop by and see whats what.
Imo, based on my DD, MLGT is a super home run.
MLGT: News release on>China>social>media>merger>pending>Expecting>news> release>for>US>investors>at>any>time.
Great op for MLGT current investors to load up on whatever is left of the tiny 24M float.
NOTE: SnapChat gearing up to make their Spectacles product available for China SnapChat like services?
http://www.businessinsider.com/snapchat-china-office-spectacles-2016-12
MLGT Chinese RM 24mill FLT: 3 Silicon>Valley-types>now>at>Helm>Of>
China>SnapChat>
MLGT is now a hot Asian social media play.
Management are all top tier tech players.
These young guys know what they are doing. The fact that they are now running a company trading in the American stock market is a feather in their cap and an impetus to crank up the volume.
Incredible turn of events for MLGT:
From 4/5/17 8-K:
Upon closing, the following person are appointed as our directors and officers effective on March 31, 2017:
Jiyin Li, Age:30, Position:Chairman
Huibin Su. Age:37 Position: Director, Chief Executive Officer and Chief Financial Officer
Zizhong Huang, Age; 28 Position: Chief Operating Officer
Mr. Li, age 30, has served as the Chairman of Shenzhen Chuangxiang Network Technology Co., Ltd, a company that engages in the development of mobile and internet software products. From August 2015 to June 2016, he was also the CEO of Shenzhen Chuangxiang Network Technology Co. Ltd. From October 2012 to June 2015, he served as the Deputy General Manager of Shenzhen E-Life Technology Co., Ltd., a technology company that develops mobile applications and online games. Mr. Li obtained his Bachelor of Art in business management from Huanghe Science &Technology College.
Mr. Li does not have any family relationship with any director or executive officer of the Company and has not been involved in any transaction with the Company during the past two years that would require disclosure under Item 404(a) of Regulation S-K.
Mr. Su, age 37, has served as the CEO and CFO of Shenzhen Chuangxiang Network Technology Co., Ltd since June 2016. From January 2015 to May 2016, he served as the CFO of Guangzhou Honghuayuan Investments Limited, an investment company that specializes in real estate related investments and fund management. From January 2012 to February 2014, he served as the CFO of Guangzhou Wancai Group Limited, a real estate and tourism development company. From August 2002 to December 2011, he served as the Finance Supervisor of Guangzhou Pharmaceutical Holdings Limited, a pharmaceutical wholesaler and distribution company. Mr. Su obtained his Master Degree in Business Administration from Sun Yat-Sen University.
Mr. Su does not have any family relationship with any director or executive officer of the Company and has not been involved in any transaction with the Company during the past two years that would require disclosure under Item 404(a) of Regulation S-K.
Mr. Huang, age 28, has served as the COO of Shenzhen Chuangxiang Network Technology Co., Ltd since July 2016. From January 2015 to June 2016, Mr. Li was the co-founder and COO of Dongguan Houhai Asset Management Co., Ltd., an investment company that specializes in equity investments and private fund management. From July 2012 to December 2014, he served as the business manager of Dongguan Rural Commercial Bank. Mr. Huang obtained his Bachelor in business administration from South China Agricultural University.
Mr. Huang does not have any family relationship with any director or executive officer of the Company and has not been involved in any transaction with the Company during the past two years that would require disclosure under Item 404(a) of Regulation S-K.
NOTE: These talented young guys have the backing and full support, including major financial backing of the Aussie tech investment powerhouse Pacific Current Group (ASX:PAC), via their subsidiary, Northern Lights.
Link:
http://paccurrent.com/
Big spreads...usually indicates BIG>Jump>UP>SOON
WARNING: Don't Get Caught>Flipping>MMEX>FINANCING>News>ANYTIME>Now
There are links to Pics of MMEX New>IR>Jen>Zimmons>with>Trump>at> Party's/Fund Raisers.
PREDICTION: Trump will Soon>Highlight>MMEX>as>First>New>Oil>Refinery>in>40 Years!
ALSO AS A Boost>To>Americas>Oil>industry:
WARNING: Don't Get Caught>Flipping>MMEX>FINANCING>News>ANYTIME>Now
Blah..>Hanks>"you>don't>go>this>far>without>financing>ALREADY>LINED>UP> ">MMEX>has>ALL Top>Tier>Partners.
WARNING: Don't Get Caught Flipping>MMEX>FINANCING>News>ANYTIME>Now.
Exactly! 1 little $145k note is a>drop>in>the>Ocean>AND>can>ONLY>be>sold>at>.03>MINIMUM
MMEXCELLENT! Hold FOR DIMES!
WARNING: Don't Get Caught Flipping>MMEX>FINANCING>News>ANYTIME>Now.
MMEX ONE PR Away From .05-.10>(NEWS>ANYTIME>ANYDAY>)>Dont>Flippit!
MMEX 8k Indicates That>The>Real>Launch>Pad>Begins>@>.03>MINIMUM!
DONT BE OUT WHEN MMEX FINANCING NEWS HITS!
Hanks>said,"You>Don't>Go>This>Far>Without>Financing>ALREADY>LINED>UP> ">MMEX>has>ALL Top>Tier>Partners.
This link is readable on a PC to the end and Hanks himself says, "you don't go this far without financing"
http://m.fortstocktonpioneer.com/news/article_c095e8d2-0442-11e7-b6f9-ef65c47e9598.html?mode=jqm
Great Post & DD From an Investor;"Spoke with>the>Chamber>Of>Commerce >in Fort Stockton. They are very excited about MMEX and the permits are being fast tracked. He has met with Jack Hanks and his team on 3 separate occasions. He was impressed with their professionalism and is looking forward to adding this company to the area"
MMEX-Cellent
DONT BE OUT MMEX MONDAY>WHEN>FINANCING>NEWS>HITS!>.03>MINIMUM>8k
DONT BE OUT MMEX MONDAY>WHEN>FINANCING>NEWS>HITS!>.03>MINIMUM>8k
TVEMF>(ENDV Patented Tech) VS PEMF>(ALL Others)>COMPARISON>
Multi Dollars double digit dollars and triple digit dollars in the horizon. Anything under .10 is a gift. Soon it will be anything under .26 is a gift.
Time-Varying Electromagnetic Field (TVEMF) technology is fundamentally different from other magnetic pulse devices. TVEMF is based on the physics of electricity and magnetism as well as the physiology of cells and tissues.
PEMF devices do not produce square waves, the optimal waveform for a tissue response.
PEMF devices do not produce enough intensity to stimulate a response; most do not even produce 1 Gauss of intensity.
PEMF devices do not produce a rate of induction (slew rate) that is quick enough to penetrate deep within tissues. TVEMF produces pulses that are only 0.0001 seconds wide.
Furthermore, TVEMF features repeating patterns of pulses that are selected based on known motor-neuron stimulation patterns of musculoskeletal tissues.
Why Square Waves?
Sine waves take too long to reach their peak intensity. The lower slew rate means that they are not effective in producing a cellular/tissue response.
Triangle and sawtooth waves also suffer from a lower slew rate, meaning that they are not effective in producing a cellular/tissue response.
Endonovo’s TVEMF device produces a patented square waveform, which was proven the most effective waveform to increase cell growth and the production of over 200 growth factors and cytokines.
Cytotronics™ Platform
Our Cytotronics™ platform uses Time-Varying Electromagnetic Field (TVEMF) technology to expand and enhance the therapeutic properties of stem cells, immune cells and for use in tissue engineering. The goal of our Cytotronics™ platform is to create optimized cell-based therapies with greater therapeutic potential than the un-modulated cells currently being used in regenerative medicine.
The origins of our Cytotronics™ platform dates back to experiments conducted at NASA to expand stem cells ex vivo and to create therapies that could be used to treat astronauts during long term space exploration. The results of those experiments revealed that Time-Varying Electromagnetic Fields (TVEMF) could be used to expand stem cells in the lab and resulted in the increased expression of dozens of genes related to cell growth, tumor suppression, cell adhesion and extracellular matrix production.
A Physics Approach to Biology – Ex Vivo Modulation
We have built upon over 15 years of research and development to create a novel therapeutic paradigm – the systematic enhancement of the biological and therapeutic properties of cells ex vivo. This allows for the creation of a precise, scalable and cost effective approach to maximize the safety and effectiveness of cell-based therapies.
While our competitors are using genetic modification and pharmacological modulation to alter and enhance the biological properties of cells, we are taking A Physics Approach to Biology™ in the use of bioelectronics to create ex vivo modulated cells with enhanced biological and therapeutic properties. Using our Cytotronics™ platform, we are able to create cells that express higher levels of key genes related to stem cell maintenance, cell growth, cell homing and engraftment. Cytotronic™ expansion of peripheral blood stem cells resulted in an over 80-fold expansion of CD34+ cells in as few as 6 days.
Our Cytotronic™ platform was shown to be able to maintain normal human neural progenitor (NHNP) cells in long term culture (180 days), undifferentiated with the ability to be cryogenically preserved then subsequently reintroduced into culture with stem and progenitor markers still intact. NHNP cells that were expanded using our technology were then shown to not be tumorigenic when introduced into nude (athymic) mice for 85 days. Multi-color Fluorescence In Situ Hybridization (mFISH) showed that there was no chromosomal damage to cells subjected to Time-Varying Electromagnetic Fields (TVEMF).
Perivascular Cell Therapy Created Using Cytotronics™
Each year, an estimated 60,000 patients with leukemia and lymphoma need bone marrow transplantation. However, only 25,000 of those patients actually receive a transplant, primarily because the other 35,000 patients are unable to find a fully matched bone marrow donor.
Umbilical cord blood from newborn children is an excellent source of hematopoietic stem cells for stem cell transplants because their immune system is still immature and the stem cells have a lower probability of inducing an adverse immune response in patients. Furthermore, a perfect immunological match between donor and recipient is not necessary, unlike in bone marrow transplants.
However, in most cases a unit of umbilical cord blood contains too few stem cells to treat an adult patient and its use is confined above all to the treatment of children. Numerous patients have better matched cord blood products available (5/6 or 6/6 HLA match), however those products have low cell doses and are not suitable for use in adult patients. This is one of the reasons why less than 3 percent of cord blood collected in the United States is ever used. Low volume cord blood units present the opportunity to expand and/or enhance these unused cord blood units for the widespread use of hematopoietic stem cells in regenerative medicine.
Off-The-Shelf Therapeutic
Our Perivascular Cell Therapy is created using immunologically privileged and immune-modulating stem cells from a portion of the human umbilical cord and co-cultured with adipose-derived stem cells along with cord blood cells to create a perivascular cell mixture that can be used to treat malignant and non-malignant hematological disorders.
Endonovo’s cell therapy is an off-the-shelf therapeutic that can be stored indefinitely in a low temperature freeze without requiring cryopreservation. Our technologies are particularly suited to expand the use and effectiveness of low-volume cord blood units.
More In Vivo-Like Stem Cells
Our off-the-shelf therapeutic is created in a three-dimensional bioreactor using our proprietary Cytotronics™ platform to further expand and enhance the biological properties of the stem cells within the perivascular cell mixture. Our use of a perivascular co-culture in a three-dimensional bioreactor is meant to mimic the way that blood-forming stem cells renew and reside in the body. This simulated stem cell niche allows for the expansion of long-term self-renewing stem cells. Researchers had previously identified endothelial and perivascular cells as the cells that were functionally responsible for the maintenance of blood-forming stem cells (HSCs) in the body. Our technologies provide a method for the expansion of HSCs in an environment that resembles their native stem cell niche..
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=129419388
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=129638466
$15 million dollar cash infusion by secret health care investor. Investors keep buying at .26 average this spending half there salary buying shares on the open market. Multi Dollars double digit dollars and triple digit dollars in the horizon. Anything under .10 is a gift. Soon it will be anything under .26 is a gift.
DONT BE OUT MMEX MONDAY>WHEN>FINANCING>NEWS>HITS!>.03>MINIMUM>8k
MMEX 8k Indicates That>The>Real>Launch>Pad>Begins>@>.03>MINIMUM!
DONT BE OUT MONDAY WHEN MMEX FINANCING NEWS HTS!
BINGO! Hanks>says,you>don't>go>this>far>without>financing>ALREADY>LINED>UP> ">MMEX>has>ALL Top>Tier>Partners.
MMEX 8k Indicates That>THE>REAL>Launch>Pad>Begins>@>.03>MINIMUM!
MMEX 8k indicates that>the>Real>Launch>Pad>Begins>@>.03>MINIMUM!
BINGO! Hanks>says,"you>don't>go>this>far>without>financing>ALREADY>LINED>UP> ">MMEX>has>ALL Top>Tier>Partners.
This link is readable on a PC to the end and Hanks himself says, "you don't go this far without financing"
MMEX CEO Jack Hanks said: “the Pecos County>refinery>is>moving>forward>quickly."
GREAT News on NAFS! Spoke to CEO 4/27>was>up-beat>told>me>Fillings>done>(10k posted a few minutes after we spoke lol) Survey done ( said he's happy with 101-43 results after I asked him if he was happy with them! ) He also Said watch for PR's next few days.
BINGO! Hanks>says,"you>don't>go>this>far>without>financing>ALREADY>LINED>UP> ">MMEX>has>ALL Top>Tier>Partners.
This link is readable on a PC to the end and Hanks himself says, "you don't go this far without financing"
http://m.fortstocktonpioneer.com/news/article_c095e8d2-0442-11e7-b6f9-ef65c47e9598.html?mode=jqm
TVEMF>(ENDV Patented Tech) VS PEMF>(ALL Others)>COMPARISON>
Time-Varying Electromagnetic Field (TVEMF) technology is fundamentally different from other magnetic pulse devices. TVEMF is based on the physics of electricity and magnetism as well as the physiology of cells and tissues.
PEMF devices do not produce square waves, the optimal waveform for a tissue response.
PEMF devices do not produce enough intensity to stimulate a response; most do not even produce 1 Gauss of intensity.
PEMF devices do not produce a rate of induction (slew rate) that is quick enough to penetrate deep within tissues. TVEMF produces pulses that are only 0.0001 seconds wide.
Furthermore, TVEMF features repeating patterns of pulses that are selected based on known motor-neuron stimulation patterns of musculoskeletal tissues.
Why Square Waves?
Sine waves take too long to reach their peak intensity. The lower slew rate means that they are not effective in producing a cellular/tissue response.
Triangle and sawtooth waves also suffer from a lower slew rate, meaning that they are not effective in producing a cellular/tissue response.
Endonovo’s TVEMF device produces a patented square waveform, which was proven the most effective waveform to increase cell growth and the production of over 200 growth factors and cytokines.
Cytotronics™ Platform
Our Cytotronics™ platform uses Time-Varying Electromagnetic Field (TVEMF) technology to expand and enhance the therapeutic properties of stem cells, immune cells and for use in tissue engineering. The goal of our Cytotronics™ platform is to create optimized cell-based therapies with greater therapeutic potential than the un-modulated cells currently being used in regenerative medicine.
The origins of our Cytotronics™ platform dates back to experiments conducted at NASA to expand stem cells ex vivo and to create therapies that could be used to treat astronauts during long term space exploration. The results of those experiments revealed that Time-Varying Electromagnetic Fields (TVEMF) could be used to expand stem cells in the lab and resulted in the increased expression of dozens of genes related to cell growth, tumor suppression, cell adhesion and extracellular matrix production.
A Physics Approach to Biology – Ex Vivo Modulation
We have built upon over 15 years of research and development to create a novel therapeutic paradigm – the systematic enhancement of the biological and therapeutic properties of cells ex vivo. This allows for the creation of a precise, scalable and cost effective approach to maximize the safety and effectiveness of cell-based therapies.
While our competitors are using genetic modification and pharmacological modulation to alter and enhance the biological properties of cells, we are taking A Physics Approach to Biology™ in the use of bioelectronics to create ex vivo modulated cells with enhanced biological and therapeutic properties. Using our Cytotronics™ platform, we are able to create cells that express higher levels of key genes related to stem cell maintenance, cell growth, cell homing and engraftment. Cytotronic™ expansion of peripheral blood stem cells resulted in an over 80-fold expansion of CD34+ cells in as few as 6 days.
Our Cytotronic™ platform was shown to be able to maintain normal human neural progenitor (NHNP) cells in long term culture (180 days), undifferentiated with the ability to be cryogenically preserved then subsequently reintroduced into culture with stem and progenitor markers still intact. NHNP cells that were expanded using our technology were then shown to not be tumorigenic when introduced into nude (athymic) mice for 85 days. Multi-color Fluorescence In Situ Hybridization (mFISH) showed that there was no chromosomal damage to cells subjected to Time-Varying Electromagnetic Fields (TVEMF).
Perivascular Cell Therapy Created Using Cytotronics™
Each year, an estimated 60,000 patients with leukemia and lymphoma need bone marrow transplantation. However, only 25,000 of those patients actually receive a transplant, primarily because the other 35,000 patients are unable to find a fully matched bone marrow donor.
Umbilical cord blood from newborn children is an excellent source of hematopoietic stem cells for stem cell transplants because their immune system is still immature and the stem cells have a lower probability of inducing an adverse immune response in patients. Furthermore, a perfect immunological match between donor and recipient is not necessary, unlike in bone marrow transplants.
However, in most cases a unit of umbilical cord blood contains too few stem cells to treat an adult patient and its use is confined above all to the treatment of children. Numerous patients have better matched cord blood products available (5/6 or 6/6 HLA match), however those products have low cell doses and are not suitable for use in adult patients. This is one of the reasons why less than 3 percent of cord blood collected in the United States is ever used. Low volume cord blood units present the opportunity to expand and/or enhance these unused cord blood units for the widespread use of hematopoietic stem cells in regenerative medicine.
Off-The-Shelf Therapeutic
Our Perivascular Cell Therapy is created using immunologically privileged and immune-modulating stem cells from a portion of the human umbilical cord and co-cultured with adipose-derived stem cells along with cord blood cells to create a perivascular cell mixture that can be used to treat malignant and non-malignant hematological disorders.
Endonovo’s cell therapy is an off-the-shelf therapeutic that can be stored indefinitely in a low temperature freeze without requiring cryopreservation. Our technologies are particularly suited to expand the use and effectiveness of low-volume cord blood units.
More In Vivo-Like Stem Cells
Our off-the-shelf therapeutic is created in a three-dimensional bioreactor using our proprietary Cytotronics™ platform to further expand and enhance the biological properties of the stem cells within the perivascular cell mixture. Our use of a perivascular co-culture in a three-dimensional bioreactor is meant to mimic the way that blood-forming stem cells renew and reside in the body. This simulated stem cell niche allows for the expansion of long-term self-renewing stem cells. Researchers had previously identified endothelial and perivascular cells as the cells that were functionally responsible for the maintenance of blood-forming stem cells (HSCs) in the body. Our technologies provide a method for the expansion of HSCs in an environment that resembles their native stem cell niche..
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=129419388
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=129638466
$15 million dollar cash infusion by secret health care investor. Investors keep buying at .26 average this spending half there salary buying shares on the open market. Multi Dollars double digit dollars and triple digit dollars in the horizon. Anything under .10 is a gift. Soon it will be anything under .26 is a gift.
GREAT News on NAFS! Just spoke to CEO, sounded up-beat, told me... Fillings done & getting up-dated, Survey done ( said he's happy with results after I asked him if he was happy with them! ) At meeting now so had to cut it short. Also Said watch for PR's next few days.
Cant post any more today...last one. GLTU
MLGT 8-K CHINA RM>24mill Float: 3 Silicon Valley-types>now>at>helm>of>China>SnapChat> clone>*****24mill Float.
MLGT: Hi end Aussie tech investors part owners. Trades on ASX: PAC.
The founder of Shenzhen Zhuomeng Chuangxiang Technology Co., Ltd. is
Ming Lu Zhong.
Most of his relationship links are to Northern Lights Capital.
Relationships Link:
https://relationshipscience.com/ming-lu-zhong-p181333806
Northern Lights Capital is now Pacific Current Group. This company trades on the Aussie Stock Exchange (ASX: PAC).
Link:
http://paccurrent.com/
In December, 2016 Northern Lights (Now absorbed into Pacific Current Group), gave a funding round of $1.2M dollars to Impingo.me..........the SnapChat clone website owned by Shenzhen Zhuomeng Chuangxiang Technology Co., Ltd. I believe Impingo has also received investing rounds from other angel investors that are now alos part owners.
Link:
https://www.techinasia.com/companies/impingome
Shortly thereafter, MLGT merged with Shenzhen Zhuomeng Chuangxiang Technology Co., Ltd.
NOTE: Based on my DD, it appears that the new MLGT owners are backed by and PARTIALLY OWNED by a top tier Aussie high tech angel investing firm with a track record of investing in high end tech growth companies.
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
MLGT is now a hot Asian social media play.
Management are all top tier tech players.
These young guys know what they are doing. The fact that they are now running a company trading in the American stock market is a feather in their cap and an impetus to crank up the volume.
Incredible turn of events for MLGT
From 4/5/17 8-K:
Upon closing, the following person are appointed as our directors and officers effective on March 31, 2017:
Jiyin Li, Age:30, Position:Chairman
Huibin Su. Age:37 Position: Director, Chief Executive Officer and Chief Financial Officer
Zizhong Huang, Age; 28 Position: Chief Operating Officer
Mr. Li, age 30, has served as the Chairman of Shenzhen Chuangxiang Network Technology Co., Ltd, a company that engages in the development of mobile and internet software products. From August 2015 to June 2016, he was also the CEO of Shenzhen Chuangxiang Network Technology Co. Ltd. From October 2012 to June 2015, he served as the Deputy General Manager of Shenzhen E-Life Technology Co., Ltd., a technology company that develops mobile applications and online games. Mr. Li obtained his Bachelor of Art in business management from Huanghe Science &Technology College.
Mr. Li does not have any family relationship with any director or executive officer of the Company and has not been involved in any transaction with the Company during the past two years that would require disclosure under Item 404(a) of Regulation S-K.
Mr. Su, age 37, has served as the CEO and CFO of Shenzhen Chuangxiang Network Technology Co., Ltd since June 2016. From January 2015 to May 2016, he served as the CFO of Guangzhou Honghuayuan Investments Limited, an investment company that specializes in real estate related investments and fund management. From January 2012 to February 2014, he served as the CFO of Guangzhou Wancai Group Limited, a real estate and tourism development company. From August 2002 to December 2011, he served as the Finance Supervisor of Guangzhou Pharmaceutical Holdings Limited, a pharmaceutical wholesaler and distribution company. Mr. Su obtained his Master Degree in Business Administration from Sun Yat-Sen University.
Mr. Su does not have any family relationship with any director or executive officer of the Company and has not been involved in any transaction with the Company during the past two years that would require disclosure under Item 404(a) of Regulation S-K.
Mr. Huang, age 28, has served as the COO of Shenzhen Chuangxiang Network Technology Co., Ltd since July 2016. From January 2015 to June 2016, Mr. Li was the co-founder and COO of Dongguan Houhai Asset Management Co., Ltd., an investment company that specializes in equity investments and private fund management. From July 2012 to December 2014, he served as the business manager of Dongguan Rural Commercial Bank. Mr. Huang obtained his Bachelor in business administration from South China Agricultural University.
Mr. Huang does not have any family relationship with any director or executive officer of the Company and has not been involved in any transaction with the Company during the past two years that would require disclosure under Item 404(a) of Regulation S-K.
NOTE: These talented young guys have the backing and full support, including major financial backing of the Aussie tech investment powerhouse Pacific Current Group (ASX:PAC), via their subsidiary, Northern Lights.
Link:
Pacific Current Group | Global Multi-Boutique Manager
Hanks>said,"You>Don't>Go>This>Far>Without>Financing>ALREADY>LINED-UP> ">MMEX>has>ALL Top>Tier>Partners.
This link is readable on a PC to the end and Hanks himself says, "you don't go this far without financing"
http://m.fortstocktonpioneer.com/news/article_c095e8d2-0442-11e7-b6f9-ef65c47e9598.html?mode=jqm
MMEX Going Up On A-Lot Less>Volume>Now-BOOM-SOON!
MMEX ONE PR Away From .05-.10>(NEWS>ANYTIME>ANYDAY>)>Dont>Flippit!